Drugs / FTD/TPI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04280536 | Aug 2019 → Jun 2026 overdue | breast cancer | National University Hospital, Singapore | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FTD/TPI | “Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.” NCT04280536 ↗ |
| Route | Oral | “Oral FTD/TPI at RP2D will be administered” NCT04280536 ↗ |